- Home
- TARA vs SGMO Comparison
TARA vs SGMO Comparison
Compare TARA & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- SGMO
- Stock Information
- Founded
- TARA N/A
- SGMO 1995
- Country
- TARA United States
- SGMO United States
- Employees
- TARA N/A
- SGMO N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TARA Health Care
- SGMO Health Care
- Exchange
- TARA Nasdaq
- SGMO Nasdaq
- Market Cap
- TARA 126.5M
- SGMO 122.8M
- IPO Year
- TARA N/A
- SGMO 2000
- Fundamental
- Price
- TARA $2.86
- SGMO $0.54
- Analyst Decision
- TARA Strong Buy
- SGMO Buy
- Analyst Count
- TARA 7
- SGMO 6
- Target Price
- TARA $20.67
- SGMO $4.50
- AVG Volume (30 Days)
- TARA 452.7K
- SGMO 6.1M
- Earning Date
- TARA 08-05-2025
- SGMO 08-05-2025
- Dividend Yield
- TARA N/A
- SGMO N/A
- EPS Growth
- TARA N/A
- SGMO N/A
- EPS
- TARA N/A
- SGMO N/A
- Revenue
- TARA N/A
- SGMO $63,756,000.00
- Revenue This Year
- TARA N/A
- SGMO N/A
- Revenue Next Year
- TARA N/A
- SGMO N/A
- P/E Ratio
- TARA N/A
- SGMO N/A
- Revenue Growth
- TARA N/A
- SGMO 239.92
- 52 Week Low
- TARA $1.60
- SGMO $0.30
- 52 Week High
- TARA $10.48
- SGMO $3.18
- Technical
- Relative Strength Index (RSI)
- TARA 43.02
- SGMO 54.59
- Support Level
- TARA $3.12
- SGMO $0.41
- Resistance Level
- TARA $3.10
- SGMO $0.51
- Average True Range (ATR)
- TARA 0.19
- SGMO 0.05
- MACD
- TARA -0.01
- SGMO 0.01
- Stochastic Oscillator
- TARA 17.19
- SGMO 74.39
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.